The Ministry of Health of Russia has registered the medicinal product “Paroxetine film-coated tablets, 20 mg, 30 mg” manufactured by FSUE Moscow Endocrine Plant, marketing authorization LP-004697, registration date 13/02/2018.
As per pharmacotherapeutic group, the medicinal product is classified as antidepressant and is “Paxil” product generic. The product is on the Vital and Essential Drugs List (VED).
Indications for the use of the medicinal product are: depression, obsessive compulsory disorder, panic disorder, social anxiety disorder, general anxiety disorder, post-traumatic stress disorder.
Efficiency and safety profile has been approved in bioavailability and bioequivalence studies in comparison to “Paxil” reference product.
The Enterprise plans to release first product commercial batches in April of 2018.
Comment type is not specified in the component properties.